• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Modified Split-Thickness Corneal Patch Graft for Conjunctival Erosions in Patients With the Port Delivery System Implant: Surgical Technique and Long-Term Outcomes.改良分层角膜贴片移植术治疗植入眼内递送系统患者的结膜糜烂:手术技术及长期疗效
J Vitreoretin Dis. 2023 Aug 11;7(5):420-423. doi: 10.1177/24741264231191612. eCollection 2023 Sep-Oct.
2
Endophthalmitis in Eyes Treated with the Port Delivery System with Ranibizumab: Summary of Cases during Clinical Trial Development.采用雷珠单抗眼内注射缓释系统治疗的眼内炎:临床试验开发期间的病例总结
Ophthalmol Retina. 2025 Feb;9(2):127-143. doi: 10.1016/j.oret.2024.08.005. Epub 2024 Aug 16.
3
Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results.载 ranibizumab 的 PORT 给药系统治疗新生血管性年龄相关性黄斑变性的 Archway 三期临床试验:2 年结果。
Ophthalmology. 2023 Jul;130(7):735-747. doi: 10.1016/j.ophtha.2023.02.024. Epub 2023 Mar 2.
4
Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.[研究名称] 研究:采用雷珠单抗的输送系统治疗新生血管性年龄相关性黄斑变性的随机 3 期临床试验。
Ophthalmology. 2022 Mar;129(3):295-307. doi: 10.1016/j.ophtha.2021.09.016. Epub 2021 Sep 29.
5
Management of Key Ocular Adverse Events in Patients Implanted with the Port Delivery System with Ranibizumab.接受雷珠单抗 port 给药系统治疗患者的主要眼部不良事件的管理。
Ophthalmol Retina. 2022 Nov;6(11):1028-1043. doi: 10.1016/j.oret.2022.05.011. Epub 2022 May 16.
6
The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial.雷珠单抗玻璃体腔注射给药系统治疗新生血管性年龄相关性黄斑变性的随机 2 期临床试验结果
Ophthalmology. 2019 Aug;126(8):1141-1154. doi: 10.1016/j.ophtha.2019.03.036. Epub 2019 Apr 1.
7
Systematic Literature Reviews Comparing the Long-Term Safety Outcomes for the Port Delivery System with Ranibizumab (PDS) Versus Other Ocular Implants.比较雷珠单抗经端口递送系统(PDS)与其他眼内植入物的长期安全性结果的系统文献综述。
Ophthalmol Ther. 2024 Sep;13(9):2303-2329. doi: 10.1007/s40123-024-01001-1. Epub 2024 Aug 1.
8
End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.抗 VEGF 药物 PORT 研究的 Ladder 阶段 2 试验终点结果:用于新生血管性年龄相关性黄斑变性的雷珠单抗经 PORT 给药系统给药
Ophthalmol Retina. 2021 Aug;5(8):775-787. doi: 10.1016/j.oret.2020.11.004. Epub 2020 Nov 18.
9
Implantation Site of a Port Delivery System With Ranibizumab: Anterior Segment Optical Coherence Tomography Evaluation.雷珠单抗眼内注射系统植入部位:眼前节光学相干断层扫描评估
J Vitreoretin Dis. 2022 Aug 4;6(5):347-350. doi: 10.1177/24741264221105809. eCollection 2022 Sep-Oct.
10
Cost of Ranibizumab Port Delivery System vs Intravitreal Injections for Patients With Neovascular Age-Related Macular Degeneration.雷珠单抗注射给药系统与玻璃体内注射治疗新生血管性年龄相关性黄斑变性患者的成本比较。
JAMA Ophthalmol. 2022 Jul 1;140(7):716-723. doi: 10.1001/jamaophthalmol.2022.1819.

本文引用的文献

1
Management of Key Ocular Adverse Events in Patients Implanted with the Port Delivery System with Ranibizumab.接受雷珠单抗 port 给药系统治疗患者的主要眼部不良事件的管理。
Ophthalmol Retina. 2022 Nov;6(11):1028-1043. doi: 10.1016/j.oret.2022.05.011. Epub 2022 May 16.
2
Conjunctiva and Tenon's Capsule Handling in the Port Delivery System with Ranibizumab Implant Insertion Procedure: Surgical Pearls.结膜和 Tenon 囊在雷珠单抗植入物插入术中的 Port 输送系统处理:手术要点。
Ophthalmic Surg Lasers Imaging Retina. 2022 May;53(5):266-273. doi: 10.3928/23258160-20220415-03. Epub 2022 May 1.
3
Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.[研究名称] 研究:采用雷珠单抗的输送系统治疗新生血管性年龄相关性黄斑变性的随机 3 期临床试验。
Ophthalmology. 2022 Mar;129(3):295-307. doi: 10.1016/j.ophtha.2021.09.016. Epub 2021 Sep 29.
4
The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial.雷珠单抗玻璃体腔注射给药系统治疗新生血管性年龄相关性黄斑变性的随机 2 期临床试验结果
Ophthalmology. 2019 Aug;126(8):1141-1154. doi: 10.1016/j.ophtha.2019.03.036. Epub 2019 Apr 1.
5
Glaucoma drainage devices: risk of exposure and infection.青光眼引流装置:暴露与感染风险
Am J Ophthalmol. 2015 Sep;160(3):516-521.e2. doi: 10.1016/j.ajo.2015.05.025. Epub 2015 May 30.
6
Risk factors for exposure of glaucoma drainage devices: a retrospective observational study.青光眼引流装置暴露的危险因素:一项回顾性观察研究。
BMJ Open. 2014 May 2;4(5):e004560. doi: 10.1136/bmjopen-2013-004560.
7
Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up.术后五年随访中 Tube Versus Trabeculectomy(TVT)研究中的并发症。
Am J Ophthalmol. 2012 May;153(5):804-814.e1. doi: 10.1016/j.ajo.2011.10.024. Epub 2012 Jan 14.

改良分层角膜贴片移植术治疗植入眼内递送系统患者的结膜糜烂:手术技术及长期疗效

Modified Split-Thickness Corneal Patch Graft for Conjunctival Erosions in Patients With the Port Delivery System Implant: Surgical Technique and Long-Term Outcomes.

作者信息

Ebert Jared J, Shildkrot Yevgeniy Eugene, Menezes Alicia, Miller Daniel M

机构信息

Department of Ophthalmology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Cincinnati Eye Institute, Cincinnati, OH, USA.

出版信息

J Vitreoretin Dis. 2023 Aug 11;7(5):420-423. doi: 10.1177/24741264231191612. eCollection 2023 Sep-Oct.

DOI:10.1177/24741264231191612
PMID:37706090
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10496813/
Abstract

To describe the surgical technique and long-term outcomes of a modified split-thickness corneal patch grafting for conjunctival erosions that can be seen in patients with the Port Delivery System (PDS) implant. By way of retrospective review of medical records, this interventional case series identified 2 cases in which modified split-thickness corneal patch grafting was used to repair conjunctival erosion in patients with the PDS implant. The surgical approach involved creating a small opening in the corneal graft over the center of the PDS implant to improve visibility and allow for easier access during subsequent refill-exchange procedures. At the last follow-up of 6.9 years and 5.6 years, there was no recurrence of conjunctival erosions in either patient. The PDS implants remained well covered with the split-thickness corneal graft and had undergone multiple implant refills without complication or difficulty. Modified split-thickness corneal patch grafting with central graft aperture offers another option for long-term successful management of conjunctival erosions in patients with a PDS, especially those who have failed prior repair, by allowing sufficient visibility and access for subsequent refill-exchange procedures.

摘要

描述改良的中厚角膜补片移植术治疗结膜糜烂的手术技术及长期效果,结膜糜烂可见于接受眼内药物缓释系统(PDS)植入的患者。通过回顾病历,本干预性病例系列研究确定了2例采用改良中厚角膜补片移植术修复PDS植入患者结膜糜烂的病例。手术方法包括在PDS植入物中心上方的角膜移植片上开一个小开口,以提高视野清晰度,并便于在后续的再填充置换手术中操作。在最后随访6.9年和5.6年时,两名患者的结膜糜烂均未复发。PDS植入物仍被中厚角膜移植片良好覆盖,并且已经进行了多次植入物再填充,未出现并发症或困难。带有中央移植孔的改良中厚角膜补片移植术为PDS植入患者结膜糜烂的长期成功治疗提供了另一种选择,特别是对于那些先前修复失败的患者,因为它能为后续的再填充置换手术提供足够的视野和操作空间。